Small Trial of Alendronate Impact on the Reservoir of HIV

This clinical trial is designed to test the effects of alendronate (ALN) on people living with HIV who are already receiving antiretroviral therapy (ART). Participants are randomly assigned in a 2:1 ratio to either receive alendronate or a placebo, and neither the participants nor the researchers know who is receiving the actual treatment. The goal is to see if alendronate can reduce the size and activity of the HIV-1 reservoir in these individuals.

NCT Number	NCT07216794
Lead Sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Conditions	HIV
Enrollment	30 participants
Start Date	2026-07-08
Primary Completion	2027-03-26 (estimated)
Study Completion	2027-05-21 (estimated)
Updated on ClinicalTrials.gov	2026-08-13